

# Appendix 3E

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

*Information and documents given to ASX become ASX's property and may be made public.*

|                               |                |
|-------------------------------|----------------|
| Name of entity                | ABN/ARSN       |
| Sigma Pharmaceuticals Limited | 15 088 417 403 |

We (the entity) give ASX the following information.

### Information about buy-back

|   |                                   |  |
|---|-----------------------------------|--|
| 1 | Type of buy-back                  | On-market buy-back   |
| 2 | Date Appendix 3C was given to ASX | 13 September 2012<br>(Associated Appendix 3D dated 4 October 2013) |

### Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day

|   |  | Before previous day | Previous day |
|---|--|---------------------|--------------|
| 3 | Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received | 66,349,277          | 281,444      |
| 4 | Total consideration paid or payable for the shares/units   | \$47,078,678        | \$188,230    |

---

**Appendix 3E**  
**Daily share buy-back notice**

---

|   |                                      | Before previous day   | Previous day   |
|---|--------------------------------------|---|--|
| 5 | If buy-back is an on-market buy-back | Highest price paid:<br>\$0.8525<br><br>Lowest price paid:<br>\$0.5600 | Highest price paid:<br>\$0.6700<br><br>Lowest price paid:<br>\$0.6650<br><br>Highest price allowed<br>under rule 7.33:<br>\$0.7025 |

**How many shares/units may still be bought back?**

|   |   |            |
|---|---|------------|
| 6 | If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back | 51,999,631 |
|---|---|------------|

**Compliance statement**

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

*or, for trusts only:*

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here:

(Director/Company secretary)

Date: 4 April 2014

Print name:

SUE MORGAN

== == == == ==

---